Neo-adjuvant chemotherapy in non-small cell lung cancer (NSCLC)
نویسندگان
چکیده
منابع مشابه
Carboplatin-pemetrexed adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): a phase II study.
BACKGROUND The aim of this study was to determine the progression-free survival (PFS) and toxicity associated with adjuvant administration of carboplatin and pemetrexed for completely resected patients with stage IB, II and IIIA non-small cell lung cancer (NSCLC). PATIENTS AND METHODS Forty-five eligible NSCLC patients received surgical resection for pathological stage IB, II or IIIA followed...
متن کاملAdjuvant chemotherapy for completely resected non-small-cell lung cancer.
PURPOSE To conduct a systematic review and to evaluate the impact of postoperative adjuvant chemotherapy on the survival of patients with completely resected non-small cell lung cancer. METHODS Relevant randomized trials and meta-analyses, published as articles or abstracts, were identified through electronic and hand searches by two reviewers. RESULTS Seven meta-analyses and 26 randomized ...
متن کاملAdjuvant chemotherapy for non-small cell lung cancer.
BACKGROUND Adjuvant chemotherapy (ACT) is known to improve survival in patients with early-stage non-small cell lung cancer. Herein, we describe chemotherapy regimens used, dose modifications, survival, and treatment-related toxicity in the general population. METHODS All cases of non-small cell lung cancer diagnosed in Ontario in the period 2004-2006 who underwent surgical resection (n = 335...
متن کاملAdjuvant chemotherapy for resected non-small cell lung cancer.
Surgery remains the mainstay of therapy for early stage non-small cell lung cancer (NSCLC), but even for stage IA, disease relapse rates remain as high as 30%. Patients with completely resected (R0) N1 disease have about a 50% chance of relapse. In the past 5 years, the benefit of adjuvant chemotherapy has finally been demonstrated for patients with lung cancer. Improvements of 5% to 10% 5-year...
متن کاملAdjuvant Chemotherapy for Resected Non–Small-Cell Lung Cancer
Because of the high rate of distant disease recurrence, the 5-year survival of patients who have undergone complete surgical resection of localized non–small-cell lung cancer (NSCLC) is approximately 50%. Initial results from early studies of adjuvant postoperative chemotherapy reported an adverse effect of alkylating agent and older chemotherapy regimens on survival. Cisplatin-based combinatio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2006
ISSN: 0923-7534
DOI: 10.1093/annonc/mdj951